CA2498772A1 - Molecules pna modifiees - Google Patents

Molecules pna modifiees Download PDF

Info

Publication number
CA2498772A1
CA2498772A1 CA002498772A CA2498772A CA2498772A1 CA 2498772 A1 CA2498772 A1 CA 2498772A1 CA 002498772 A CA002498772 A CA 002498772A CA 2498772 A CA2498772 A CA 2498772A CA 2498772 A1 CA2498772 A1 CA 2498772A1
Authority
CA
Canada
Prior art keywords
pna
thymine
nucleic acid
peptide nucleic
boc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002498772A
Other languages
English (en)
Inventor
Palle Rasmussen
Niels Montano Frandsen
Marlene Nyborg
Frank Winther Rasmussen
Ramin Hamzavi
Peter Eigild Nielsen
Soren Kjaerulff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Santaris Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma AS filed Critical Santaris Pharma AS
Publication of CA2498772A1 publication Critical patent/CA2498772A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne de nouveaux médicaments destinés à être utilisés pour combattre diverses maladies. D'une manière plus spécifique, l'invention concerne des médicaments à base d'acide nucléique peptidique (PNA), qui sont éventuellement modifiés afin d'obtenir de nouvelles molécules PNA avec une administration spécifique de cellules.
CA002498772A 2002-09-11 2003-09-11 Molecules pna modifiees Abandoned CA2498772A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DKPA200201334 2002-09-11
DKPA200201334 2002-09-11
DKPA200201786 2002-11-19
DKPA200201786 2002-11-19
DKPA200201956 2002-12-20
DKPA200201956 2002-12-20
DKPA200300600 2003-04-16
DKPA200300600 2003-04-16
PCT/DK2003/000588 WO2004024757A2 (fr) 2002-09-11 2003-09-11 Molecules pna modifiées

Publications (1)

Publication Number Publication Date
CA2498772A1 true CA2498772A1 (fr) 2004-03-25

Family

ID=31999319

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002498772A Abandoned CA2498772A1 (fr) 2002-09-11 2003-09-11 Molecules pna modifiees

Country Status (4)

Country Link
EP (1) EP1543019A2 (fr)
AU (1) AU2003260289A1 (fr)
CA (1) CA2498772A1 (fr)
WO (1) WO2004024757A2 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2685127C (fr) * 2007-04-23 2019-01-08 Alnylam Pharmaceuticals, Inc. Glycoconjugues d'agents d'interference arn
WO2009082606A2 (fr) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Conjugués du folate
WO2009073809A2 (fr) 2007-12-04 2009-06-11 Alnylam Pharmaceuticals, Inc. Conjugués glucidiques utilisés en tant qu'agents d'administration pour des oligonucléotides
WO2012138955A2 (fr) * 2011-04-08 2012-10-11 Ly Danith H Acides nucléiques gamma-peptidiques contenant du minipeg, conformationnellement préorganisés
WO2013033230A1 (fr) 2011-08-29 2013-03-07 Isis Pharmaceuticals, Inc. Complexes oligomère-conjugué et leur utilisation
US10221216B2 (en) 2013-04-11 2019-03-05 Carnegie Mellon University Template-directed γPNA synthesis process and γPNA targeting compounds
WO2014169206A2 (fr) 2013-04-11 2014-10-16 Carnegie Mellon University Composés à nucléobases divalentes et leurs utilisations
DK2992098T3 (da) 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
WO2015168172A1 (fr) 2014-04-28 2015-11-05 Isis Pharmaceuticals, Inc. Composés oligomères modifiés par liaison
EA036496B1 (ru) 2014-05-01 2020-11-17 Ионис Фармасьютикалз, Инк. Конъюгированные олигонуклеотиды для модулирования экспрессии фактора комплемента b
US9382540B2 (en) 2014-05-01 2016-07-05 Isis Pharmaceuticals, Inc Compositions and methods for modulating angiopoietin-like 3 expression
BR112016022742B1 (pt) 2014-05-01 2022-06-14 Ionis Pharmaceuticals, Inc Composto químico, composição compreendendo o composto e uso dos mesmos
HUE052709T2 (hu) 2014-05-01 2021-05-28 Ionis Pharmaceuticals Inc Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
WO2015179693A1 (fr) 2014-05-22 2015-11-26 Isis Pharmaceuticals, Inc. Composés antisens conjugués et leur utilisation
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
KR102545316B1 (ko) 2014-11-10 2023-06-22 알닐람 파마슈티칼스 인코포레이티드 Ｂ형 간염 바이러스(ｈｂｖ) ｉｒｎａ 조성물 및 그의 이용 방법
MX2018000412A (es) 2015-07-10 2018-03-14 Ionis Pharmaceuticals Inc Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
CN108513588A (zh) 2015-09-24 2018-09-07 Ionis制药公司 Kras表达的调节剂
PL4119569T3 (pl) 2015-11-06 2024-11-18 Ionis Pharmaceuticals, Inc. Sprzężone związki antysensowne do zastosowania w terapii
KR20250078597A (ko) 2015-11-06 2025-06-02 아이오니스 파마수티컬즈, 인코포레이티드 아포리포프로테인 (a) 발현 조정
CA3011946A1 (fr) 2016-03-07 2017-09-14 Arrowhead Pharmaceuticals, Inc. Ligands de ciblage pour composes therapeutiques
EP3484524B1 (fr) 2016-07-15 2022-11-09 Ionis Pharmaceuticals, Inc. Composés et procédés de modulation de smn2
SG11201901841TA (en) 2016-09-02 2019-03-28 Arrowhead Pharmaceuticals Inc Targeting ligands
JP7573965B2 (ja) 2016-09-26 2024-10-28 カーネギー メロン ユニバーシティ 二価核酸塩基化合物およびそれらの使用
US11400161B2 (en) 2016-10-06 2022-08-02 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
CN110740994A (zh) * 2017-03-23 2020-01-31 特鲁科德基因修复公司 具有受正交保护的酯部分的肽核酸(pna)单体
JOP20190215A1 (ar) 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc مُعدّلات التعبير الوراثي عن pcsk9
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
AU2019206731A1 (en) 2018-01-15 2020-07-30 Ionis Pharmaceuticals, Inc. Modulators of DNM2 expression
WO2019157531A1 (fr) 2018-02-12 2019-08-15 Ionis Pharmaceuticals, Inc. Composés modifiés et leurs utilisations
CU20200082A7 (es) 2018-05-09 2021-06-08 Ionis Pharmaceuticals Inc Compuestos y métodos para la reducción de la expresión de fxi
US12496311B2 (en) 2018-07-17 2025-12-16 Aronora, Inc. Methods for safely reducing thrombopoietin
EP3833397A4 (fr) 2018-08-08 2023-06-14 Arcturus Therapeutics, Inc. Compositions et agents contre la stéatohépatite non alcoolique
JP7625512B2 (ja) 2018-08-13 2025-02-03 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｂ型肝炎ウイルス（ＨＢＶ）ｄｓＲＮＡ物質組成物およびその使用方法
TW202542311A (zh) 2018-09-19 2025-11-01 美商Ionis製藥公司 Pnpla3表現之調節劑
CR20210395A (es) 2018-12-21 2021-11-05 Ionis Pharmaceuticals Inc Moduladores de la expresión de hsd17b13
WO2021074772A1 (fr) 2019-10-14 2021-04-22 Astrazeneca Ab Modulateurs de l'expression de pnpla3
CN120505310A (zh) 2020-02-28 2025-08-19 Ionis制药公司 用于调节smn2的化合物和方法
CN115916262A (zh) 2020-04-21 2023-04-04 旗舰创业股份有限公司 双官能分子及其使用方法
LT4136092T (lt) 2020-11-18 2024-09-25 Ionis Pharmaceuticals, Inc. Junginiai ir būdai, skirti angiotenzinogeno raiškos moduliavimui
US12042509B2 (en) 2021-10-01 2024-07-23 Adarx Pharmaceuticals, Inc. Prekallikrein-modulating compositions and methods of use thereof
TW202448484A (zh) 2023-04-20 2024-12-16 美商雅迪克斯製藥公司 Ｍａｐｔ調節組合物及其使用方法
WO2024238396A1 (fr) 2023-05-12 2024-11-21 Adarx Pharmaceuticals, Inc. Composés conjugués à un ligand de nmda et leurs utilisations
CN121335980A (zh) 2023-05-26 2026-01-13 阿达尔克斯制药有限公司 Sod1调节组合物及其使用方法
EP4731763A1 (fr) 2023-06-20 2026-04-29 Adarx Pharmaceuticals, Inc. Compositions modulant lrrk2 et leurs procédés d'utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2291839A1 (fr) * 1997-05-28 1998-12-03 Peter E. Nielsen Acides nucleiques peptidiques conjugues presentant une fixation cellulaire accrue

Also Published As

Publication number Publication date
AU2003260289A1 (en) 2004-04-30
EP1543019A2 (fr) 2005-06-22
WO2004024757A2 (fr) 2004-03-25
WO2004024757A3 (fr) 2004-04-29

Similar Documents

Publication Publication Date Title
CA2498772A1 (fr) Molecules pna modifiees
JP2758988B2 (ja) ペプチド核酸
US7550582B2 (en) Polyamide nucleic acid derivatives and agents, and processes for preparing them
AU698210B2 (en) Polyamide-oligonucleotide derivatives, their preparation and use
US20020188101A1 (en) Conjugated peptide nucleic acids having enhanced cellular uptake
US20040072743A1 (en) Pharmaceutical composition of modified pna molecules
RS20100249A (sr) Konjugati i postupci za njihovo dobijanje, i njihova upotreba za transport molekula kroz biološke membrane
US7241882B2 (en) Polyamide nucleic acid derivatives, and agents, and processes for preparing them
JP2004514427A (ja) Ｐｎａ類似物
Zatsepin et al. Synthesis of 2′-modified oligonucleotides containing aldehyde or ethylenediamine groups
US7442788B2 (en) Antisense molecules and method of controlling expression of gene function by using the same
WO2002053574A2 (fr) Molecules pna modifiees
WO1995020404A1 (fr) Oligonucleotides a ions apparies formant des helices triples, procedes pour les realiser et leur utilisation
US6872809B2 (en) Nucleoside derivatives
US20250171776A1 (en) Non-canonical cell-penetrating peptides for antisense oligomer delivery
WO2004001055A2 (fr) Promedicaments a base de pna
WO1993020090A1 (fr) Oligonucleotides a ions apparies et leurs procedes de preparation
DE19635064A1 (de) Nukleinsäure-bindende Oligomere

Legal Events

Date Code Title Description
FZDE Dead